Maria Schwab1, Rainer Hofmann2, Hendrik Heers2, Axel Hegele2. 1. Department of Urology and Pediatric Urology, University Medical Center, Marburg, Germany schwab.maria@gmx.de. 2. Department of Urology and Pediatric Urology, University Medical Center, Marburg, Germany.
Abstract
BACKGROUND/AIM: Since the advent of targeted therapeutics, paradigms in metastatic renal cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data from randomized controlled trials can be transferred into real-world settings. PATIENTS AND METHODS: All patients with mRCC treated from 2006-2015 at the Department of Urology (Marburg-Germany) were retrospectively analyzed. Collected data include: Patient demographics, tumor characteristics, efficacy, safety, and used therapy sequences. RESULTS: In total, 197 patients with mRCC were identified. About one third of patients reached third-line therapy. Median overall survival in real-world amounted to 25.8 months with a five-year survival rate of 30% with significant differences between IMDC risk groups (p<0.01). Response rates were highest using tyrosine kinase inhibitor (TKI). Patients with response to therapy showed significantly improved survival (p<0.05). Side-effects in each therapy line were manageable in daily practice. CONCLUSION: Our data suggest that targeted therapy in the treatment of mRCC is effective and safe in daily clinical practice and for real-world patients. Copyright
BACKGROUND/AIM: Since the advent of targeted therapeutics, paradigms in metastatic renal cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data from randomized controlled trials can be transferred into real-world settings. PATIENTS AND METHODS: All patients with mRCC treated from 2006-2015 at the Department of Urology (Marburg-Germany) were retrospectively analyzed. Collected data include: Patient demographics, tumor characteristics, efficacy, safety, and used therapy sequences. RESULTS: In total, 197 patients with mRCC were identified. About one third of patients reached third-line therapy. Median overall survival in real-world amounted to 25.8 months with a five-year survival rate of 30% with significant differences between IMDC risk groups (p<0.01). Response rates were highest using tyrosine kinase inhibitor (TKI). Patients with response to therapy showed significantly improved survival (p<0.05). Side-effects in each therapy line were manageable in daily practice. CONCLUSION: Our data suggest that targeted therapy in the treatment of mRCC is effective and safe in daily clinical practice and for real-world patients. Copyright
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Jean-Jacques Patard; Emmanuelle Leray; Nathalie Rioux-Leclercq; Luca Cindolo; Vincenzo Ficarra; Amnon Zisman; Alexandre De La Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; François Guillé; Dominique K Chopin; Peter F A Mulders; Christopher G Wood; David A Swanson; Robert A Figlin; Arie S Belldegrun; Allan J Pantuck Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud Journal: Lancet Date: 2008-07-22 Impact factor: 79.321
Authors: Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544
Authors: Robert Hawkins; Kate Fife; Michael Hurst; Meng Wang; Niroshini Naicker; Sarah Nolasco; Tim Eisen; Athena Matakidou; Jason Gordon Journal: BMC Cancer Date: 2020-07-17 Impact factor: 4.430